J&J’s diabetes drug Invokana cuts heart risk

Minneapolis: Johnson & Johnson’s pill Invokana reduced the risk of cardiovascular complications in diabetic patients, making it the second medication of its kind to help the heart, but the benefit came with an increased risk of amputations and perhaps broken bones, researchers said.

Patients given Invokana were 14% less likely to suffer a heart attack, stroke or die from heart disease than those given a placebo, according to the combined data from two studies presented at the American Diabetes Association’s annual meeting.